Annual financial results as of 31 December, 2022
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase
18/04/2023 – AB Science today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
12/04/2023 – AB Science today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a presentation on masitinib in amyotrophic lateral sclerosis (ALS) to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy…
04/04/2023 – AB Science today provides an update on the schedule for the evaluation by the European Medicines Agency (EMA) and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)